Featuring Director of R&D, Dr. Michael Joyce! Dr. Joyce’s experience bridging fundamental science with translational development strengthens $BRTX’s ability to generate compelling preclinical and clinical data, expand its intellectual property portfolio, & accelerate development.

Wishing everyone celebrating @America250 a joyful and safe holiday weekend from all of us at BioRestorative Therapies! #America250

Featuring $BRTX's VP of Biochemistry, Zachary Smith! Mr. Smith brings over 16 years of experience across medical aesthetics, biologics and capital equipment markets. He will lead revenue growth initiatives, regenerative physician channels, strategic partnerships and key accounts.

New findings presented at #ENDO2026 suggest GLP-1 therapies like tirzepatide may do more than support weight loss & activate BAT. For $BRTX, this supports the potential of combining brown adipose stem cell therapy with GLP-1s. Learn more: endocrine.org/news-and-advoc… @TheEndoSociety

$BRTX successfully completed manufacturing of its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of its vertically integrated regenerative medicine platform. 🔗 bit.ly/4oJYCBv

$BRTX is actively advancing an integrated regenerative medicine platform designed to address significant unmet needs across healthcare and aesthetics. $BRTX has multiple value creation catalysts ahead, including clinical, regulatory, commercialization, and partnership milestones.

$BRTX announces the appointment of Zachary Smith as VP of its Biocosmeceuticals Division, further strengthening its commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market. Full press release: bit.ly/4vWvA3V

Featuring $BRTX’s CFO, Robert Kristal! Robert brings a wide array of strategic and financial markets experience to the team, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations.

The $BRTX team recently visited IPS Labs to learn more about the science and expertise behind successful formulation development. Thank you to the full IPS team for providing an in-depth look at their facility, technologies, and approach to innovation!

$BRTX's fully enrolled, randomized, double-blind, sham-controlled Phase 2 study in cLDD has completed treatment administration in 99 patients, continuing Phase 3 readiness activities following @US_FDA Type B meeting alignment. Read the full press release: bit.ly/4dxJoMf

Francisco Silva brings over two decades of entrepreneurial and clinical-development experience in cell- and biologic-based therapeutics. He combines hands-on scientific expertise with commercial strategy to advance next-generation orthobiologics and cell therapies. $BRTX

Skincare is getting smart. BioCosmeceuticals’ biologic-powered products mix cutting-edge science with real cosmetic results. Learn how exosome and growth factor-based formulations are changing the game. Find out more: bit.ly/4sN69Rj $BRTX

$BRTX's CEO, Lance Alstodt, recently spoke with @Xtalks about the evolving landscape of regenerative medicine and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease. Listen here: youtube.com/watch?v=n_Z89oBe…

The last patient has been dosed in $BRTX's fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of cLDD, completing treatment administration of its lead clinical program & advancing the study into the next blinded follow-up stage. 🔗 bit.ly/4dxJoMf

Chronic lower back pain remains one of the most persistent and costly challenges in global healthcare. $BRTX's President & CEO, Lance Alstodt, shares how our team is working to redefine spine care through autologous cell therapy in this byline article: drugdeliveryleader.com/doc/s…

Today is #ClinicalTrialsDay, a celebration and recognition of participants, researchers, and @US_FDA staff. $BRTX is proud of the progress being made across our ongoing clinical trials as we work to utilize regenerative biology for longevity and healthier lives. @ACRPDC

Featuring $BRTX's Head of Global Commercialization, Crystal Romano! Crystal brings 20+ years of expertise in the medical, aesthetics, & regenerative industries. She is recognized as an expert in product development, commercialization, navigating patent & @US_FDA regulations.

$BRTX announces the presentation of new preclinical data at #ISCT26. The new data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications. Read more: bit.ly/4354Hyt @ISCTglobal

$BRTX recently announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100 at @ISCTglobal. The blinded ISCT dataset showed sustained improvements in both pain and function among patients with CLDD. 🔗 ir.biorestorative.com/news-e…

$BRTX announces expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, showing sustained improvements in both pain and function among patients with CLDD. Learn more about the data presented at @ISCTglobal: bit.ly/4no20l6 #ISCT2026